Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors
Creators
- Anthiya, Shubaash1
- Ozturk, Suleyman Can2
- Yanik, Hamdullah3
- Tavukcuoglu, Ece3
- Sahin, Adem4
- Datta, Dhrubajyoti5
- Charisse, Klaus5
- Alvarez, David Moreira6
- Loza, Maria Isabel6
- Calvo, Alfonso
- Sulheim, Einar7
- Loevenich, Simon7
- Klinkenberg, Geir7
- Schmid, Ruth7
- Manoharan, Muthiah5
- Esendagli, Gunes3
- Alonso, Maria Jose
- 1. Univ Santiago de Compostela, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela 15782, Spain
- 2. Hacettepe Univ, Res & Applicat Ctr Anim Expt, Canc Inst, Ankara, Turkiye
- 3. Hacettepe Univ, Dept Basic Oncol, Canc Inst, Ankara, Turkiye
- 4. ILKO Pharmaceut, R&D Dept, Ankara, Turkiye
- 5. Alnylam Pharmaceut, 675 West Kendall, Cambridge, MA 02142 USA
- 6. Univ Santiago de Compostela, BioFarma Res Grp, CIMUS, Santiago De Compostela, Spain
- 7. SINTEF Ind, Dept Biotechnol & Nanomed, Trondheim, Norway
Description
K-RAS is a highly relevant oncogene that is mutated in approximately 90% of pancreatic cancers and 20-25% of lung adenocarcinomas. The aim of this work was to develop a new anti-KRAS siRNA therapeutic strategy through the engineering of functionalized lipid nanoparticles (LNPs). To do this, first, a potent pan anti-KRAS siRNA sequence was chosen from the literature and different chemical modifications of siRNA were tested for their transfection efficacy (KRAS knockdown) and anti-proliferative effects on various cancer cell lines. Second, a selected siRNA candidate was loaded into tLyp-1 targeted and non-targeted lipid nanoparticles (LNPs). The biodistribution and antitumoral efficacy of selected siRNA-loaded LNP-prototypes were evaluated in vivo using a pancreatic cancer murine model (subcutaneous xenograft CFPAC-1 tumors). Our results show that tLyp-1-tagged targeted LNPs have an enhanced accumulation in the tumor compared to non-targeted LNPs. Moreover, a sig-nificant reduction in the pancreatic tumor growth was observed when the anti-KRAS siRNA treatment was combined with a classical chemotherapeutic agent, gemcitabine. In conclusion, our work demonstrates the benefits of using a targeting approach to improve tumor accumulation of siRNA-LNPs and its positive impact on tumor reduction.
Files
bib-3fa8058f-b18d-4230-acd7-b95d563a0742.txt
Files
(357 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:3552512acf64488e9e4f6d1dca9a9239
|
357 Bytes | Preview Download |